C3 Pulse Part 1
Bringing you the latest news from C3 and the world of interventional cardiology Click below to view the full C3 PULSE
TAVR: Is There Trouble in Paradise?
By Rajesh Dave I was the fortunate physician who had the privilege of performing the very first commercially approved Sapien valve procedure in the USA (2011). Since then, we have…
How to Select the Right Patient for Long-Term DAPT
Issue of Debate at C3, June 17-20, 2018 Interventional Academy Speaks with Prof David Erlinge, MD, PhD, FESC, FACC, Head, Department of Cardiology, Lund, Sweden Treatment with dual antiplatelet therapy…
TREAT: Are We One Step Closer?
TREAT: Are we one step closer? by Rajesh M. Dave, MD It is well established that Primary PCI in a timely fashion leads to the best outcomes in patients with STEMI.…
Update: ODYSSEY Outcomes
Update on ODYSSEY Outcomes – by Dr. Rajesh Dave, MD, FSCAI, FACC ODYSSEY Outcomes, the second of the cardiovascular outcomes studies with a PCSK9 inhibitor, this time in an acute…